NCR Online Journal

Epidermolysis Bullosa Epidemiology Forecast to 2030 by DelveInsight

 Breaking News
  • No posts were found

Epidermolysis Bullosa Epidemiology Forecast to 2030 by DelveInsight

August 20
17:15 2020
Epidermolysis Bullosa Epidemiology Forecast to 2030 by DelveInsight

 

(Albany, US) DelveInsight has launched a new report on Epidermolysis Bullosa Epidemiology

 

DelveInsight’s ‘Epidermolysis Bullosa – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Epidermolysis Bullosa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

 

Epidermolysis Bullosa (EB) is a group of skin diseases that cause various degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins essential for skin integrity are absent, reduced, or abnormal. It is characterized by blister formation in response to mechanical trauma. To date, there is no treatment or cure for EB. EB is generally caused by mutations involving at least 18 genes encoding structural proteins within keratin intermediate filaments, focal adhesions, desmosome cell junctions, and hemidesmosome attachment complexes, which form the intraepidermal adhesion and dermo-epidermal anchoring complex within the basement membrane zone (BMZ) of the skin and mucosae.

 

 

Request for free sample page: – https://www.delveinsight.com/sample-request/epidermolysis-bullosa-epidemiology-forecast

 

Epidermolysis Bullosa Epidemiology

 

Epidermolysis Bullosa is of several types, and three major types of Epidermolysis bullosa includes Epidermolysis bullosa simplex (EBS), junctional EB (JEB), and dystrophic EB (DEB). Assessments as per DelveInsight’s analysts show that the majority of cases of EB are Epidermolysis bullosa simplex, but similar trend is not followed by other countries. In 2017, there were 18,599 cases of EBS, 1,240 cases of JEB, and 4,960 cases of DEB in the United States. DEB is further divided as, recessive and dominant. Recessive DEB is more common than Dominant DEB.

 

Epidermolysis Bullosa Key Facts

 

  • Assessments as per DelveInsight’s analysts shows that the total prevalent population of Epidermolysis Bullosa in seven major markets was 41,509 in 2017.
  • The total diagnosed prevalent cases of Epidermolysis Bullosa in 7MM was 39,433 in 2017.
  • In 2017, there were 26,104 prevalent cases of Epidermolysis Bullosa in the United States.
  • In 2017, there were total 24,799 diagnosed prevalent cases of Epidermolysis Bullosa in the United States.
  • Among the European countries, United Kingdom had the highest prevalent population of Epidermolysis Bullosa with 5,037 cases, followed by Germany which had a prevalent population of 4,919 in 2017. On the other hand, Spain had the lowest prevalent population of 928 in 2017.
  • Japan had 1,998 prevalent cases of Epidermolysis Bullosa in 2017.

 

Epidermolysis Bullosa Report Scope

  • The Epidermolysis Bullosa report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Epidermolysis Bullosa Epidemiology Report and Model provide an overview of the risk factors and global trends of Epidermolysis Bullosa in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Epidermolysis Bullosa in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Epidermolysis Bullosa
  • The report provides the segmentation of the Epidermolysis Bullosa epidemiology

 

Download free sample page: – https://www.delveinsight.com/sample-request/epidermolysis-bullosa-epidemiology-forecast

 

Table of content

 

1. Key Insights 

2. Executive Summary of Epidermolysis Bullosa

3. Epidermolysis Bullosa: Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

 

Why should you buy this report?

 

  • The Epidermolysis Bullosa Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global Epidermolysis Bullosa market
  • Quantify patient populations in the global Epidermolysis Bullosa market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Epidermolysis Bullosa therapeutics in each of the markets covered
  • Understand the magnitude of Epidermolysis Bullosa population by its epidemiology
  • The Epidermolysis Bullosa Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Related Reports

 

 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles